IdentiRx has been focused on developing a portfolio of ophthalmic generics for the U.S. market
Opportunity to acquire portfolio of drugs in late and mid-stage development
Portfolio:
• Products in mid and late-stage development
• 3 products filed and approved
• 2 products to be filed within 12 months
60M+ addressable market with growing volumes and minimal established competition
Stay tuned for more updates.